Disc Medicine (NASDAQ:IRON) Issues Earnings Results, Beats Estimates By $0.07 EPS

Disc Medicine (NASDAQ:IRON) released its quarterly earnings results on Thursday. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07, FiscalAI reports. The firm had revenue of ($19.88) million for the quarter, compared to the consensus estimate of $0.15 million.

Disc Medicine Stock Performance

IRON stock traded down $1.85 during midday trading on Friday, reaching $66.06. 69,401 shares of the company’s stock traded hands, compared to its average volume of 754,819. The stock has a market cap of $2.49 billion, a P/E ratio of -12.39 and a beta of 0.88. The stock’s 50-day moving average is $74.70 and its 200 day moving average is $75.34. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine has a 52-week low of $30.82 and a 52-week high of $99.50.

Analyst Ratings Changes

Several brokerages have commented on IRON. Cantor Fitzgerald dropped their target price on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. TD Cowen restated a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Raymond James Financial reiterated a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Wells Fargo & Company dropped their price objective on Disc Medicine from $109.00 to $78.00 and set an “overweight” rating for the company in a research report on Tuesday, February 17th. Finally, Stifel Nicolaus cut their price objective on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.00.

Insider Buying and Selling

In related news, insider Pamela Stephenson sold 5,531 shares of Disc Medicine stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the completion of the sale, the insider owned 80,998 shares of the company’s stock, valued at $5,091,534.28. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jonathan Yen-Wen Yu sold 3,231 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total transaction of $203,100.66. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,414,806.64. The trade was a 5.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 284,761 shares of company stock worth $24,913,484 over the last three months. 3.64% of the stock is currently owned by company insiders.

Institutional Trading of Disc Medicine

Institutional investors have recently added to or reduced their stakes in the stock. First Trust Advisors LP bought a new stake in shares of Disc Medicine in the 2nd quarter worth approximately $543,000. Police & Firemen s Retirement System of New Jersey boosted its holdings in Disc Medicine by 3.3% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock worth $533,000 after purchasing an additional 215 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Disc Medicine during the 4th quarter valued at approximately $434,000. VARCOV Co. bought a new stake in Disc Medicine in the 4th quarter valued at $423,000. Finally, Verition Fund Management LLC bought a new stake in Disc Medicine during the third quarter worth about $405,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.